About Us

Board of Directors


Joshua H. Bilenker, M.D.
Chief Executive Officer

Dr. Joshua H. Bilenker, M.D., founder of Loxo Oncology, serves as President and Chief Executive Officer, and sits on the board of directors.

Previously, Dr. Bilenker was a Partner at Aisling Capital, a multi-strategy healthcare investment firm based in NY, where he remains an Operating Partner.

From 2004-2006, Dr. Bilenker was a Medical Officer at the U.S. FDA in the Office of Oncology.

Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his A.B. degree from Princeton University.

Steve Elms

Mr. Steve Elms has served on the board of directors since July 2013.

Mr. Elms is currently a Managing Partner at Aisling Capital, a leading private equity fund investing in life science companies, and serves on the board of a number of public and private life sciences companies.

Previously, Mr. Elms was a senior member of the Life Sciences Investment Banking Group of Hambrecht & Quist and was involved in over 60 financing and M&A transactions, which helped clients raise in excess of $3.3 billion in capital. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories.

Mr. Elms received an MBA from the Kellogg Graduate School of Management at Northwestern University, and a B.A. in Human Biology from Stanford University.

Keith T. Flaherty, M.D.
Director, and Chair of the SAB

Dr. Keith T. Flaherty has served as SAB Chair since company inception, and sits on the board of directors.

Dr. Flaherty is currently Director of Clinical Research and the Henri and Belinda Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, and is a Professor of Medicine at Harvard Medical School.

Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital, and in medical oncology at the University of Pennsylvania, earning board certification in these specialties.

He received his M.D. from The Johns Hopkins School of Medicine and his B.S. degree from Yale University.

Avi Z. Naider

Mr. Avi Z. Naider has served on the board of directors since September 2013.

Mr. Naider is currently Chairman and CEO of ACES Risk Management Corp.

Mr. Naider is a successful entrepreneur who has founded and managed companies in various sectors, including internet advertising and mortgage industry software. He previously worked in private equity and for the Boston Consulting Group.

Mr. Naider received his A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University, where he graduated Phi Beta Kappa.

Lori A. Kunkel, M.D.

Dr. Lori A. Kunkel has served on the board of directors since October 2014.

Dr. Kunkel served as Acting Chief Medical Officer for Loxo Oncology from October 2013 to October 2014.

As principal of LAK 505, LLC, she is a clinical/regulatory strategic advisor to public and private biotech companies in the San Francisco, San Diego, New York and Boston areas. She currently serves on the board of directors of Curis, Inc, Tocagen and Maverick Therapeutics and is a clinical advisor to Amphvena, Atreca and Verastem. Dr. Kunkel served as Chief Medical Officer at Pharmacyclics, Inc. leading integrated clinical development highlighted by the approval of IMBRUVICA. She has also served as Chief Medical Officer at Proteolix Inc. (acquired by Onyx), Syndax, and ACT Biotech.

Prior to joining the international biotechnology industry in 1995, Dr. Kunkel spent ten years in academic/clinical medicine and served as a faculty member in the Division of Hematology/Oncology’s Bone Marrow Transplant Unit at University of California, Los Angeles.

She trained in internal medicine at Baylor College of Medicine, hematology at USC and oncology at UCLA, earning board certifications in these specialties.

Alan Fuhrman

Alan Fuhrman has served on our board of directors since January 2015.

Mr. Fuhrman currently serves as CFO of Amplyx Pharmaceuticals a drug development company focused on life-threatening infections.

Prior to joining Amplyx, he served as CFO of publicly-traded Mirna Therapeutics, a clinical-stage microRNA company that merged with Synlogic in August 2017. Prior to that, Mr. Fuhrman was CFO of Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. He has also served as the CFO at Naviscan, a privately held medical imaging company, and Sonus Pharmaceuticals, a publicly traded oncology-focused biotechnology company. Earlier in his career, Mr. Fuhrman practiced as a certified public accountant with Coopers & Lybrand.

Mr. Fuhrman received a B.S. in both Business Administration and Agricultural Economics from Montana State University.

Tim Mayleben

Tim Mayleben has served on the board of directors since July 2015.

Mr. Mayleben is currently President and Chief Executive Officer at Esperion Therapeutics and has been a member of the board of directors since 2010.

Mr. Mayleben is an advisor to, investor in, and member of the board of directors of several life science companies, including Kaleo Pharma, Marinus Pharmaceuticals and the Wolverine Venture Fund.

Mr. Mayleben earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a B.B.A. from the University of Michigan, Ross School of Business.

Steve D. Harr, M.D.

Dr. Steve D. Harr joined the board of directors in November 2016.

Dr. Harr is currently the chief financial officer and head of corporate development at Juno Therapeutics, a biopharmaceutical company developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies.

Previously, Dr. Harr was managing director and head of biotechnology investment banking at Morgan Stanley. Prior to his investment banking role at Morgan Stanley, Dr. Harr was Morgan Stanley’s lead biotech research analyst and co-head of Global Healthcare Research.

Dr. Harr received a B.A. in economics from College of the Holy Cross and an M.D. from The Johns Hopkins University School of Medicine. Dr. Harr was a resident in internal medicine at the University of California, San Francisco.